BCT BriaCell Therapeutics Corp
Listings ·
BriaCell's board approved a one-for-ten share consolidation to keep its Nasdaq listing, expected to take effect August 25, 2025, subject to approval from Nasdaq and the Toronto Stock Exchange.
Nasdaq closed BriaCell's bid price matter on February 12, 2025, after an August 2024 letter cited 30 consecutive business days with closing bids below $1.00.
BriaCell Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies to treat cancer. Its lead candidate, Bria-IMT, is being advanced in combination with the immune checkpoint inhibitor Retifanlimab in a pivotal Phase 3 study in metastatic breast cancer, and it is under Fast Track Designation from the U.S. Food and Drug Administration. The company reports median overall survival of 13.3 months for the Phase 3 sequence in its metastatic breast cancer patients and 16.6 months for Phase 2 patients treated with the Phase 3 formulation since 2022. Incyte Corporation manufactures Retifanlimab, an anti-PD1 antibody. BriaCell is also running a Phase 1/2 study of Bria-OTS, a personalized off-the-shelf immunotherapy, in metastatic breast cancer, and is developing its advanced form, Bria-OTS+, as a platform for numerous types of cancer. The FDA has permitted Phase 1/2a clinical studies of Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer, with open Investigational New Drug applications for both. The company is also developing Bria-OVA+ for ovarian cancer and Bria-MEL+, a personalized whole cell melanoma immunotherapy vaccine candidate.
| Product or program | What it is | Stage |
|---|---|---|
| Bria-IMT | Targeted immunotherapy combined with Retifanlimab for metastatic breast cancer | Pivotal Phase 3 study |
| Bria-OTS | Personalized off-the-shelf immunotherapy for metastatic breast cancer | Phase 1/2 |
| Bria-OTS+ | Advanced form of Bria-OTS as a platform for numerous cancer types | In development |
| Bria-BRES+ | Immunotherapy for breast cancer | Phase 1/2a studies permitted by FDA |
| Bria-PROS+ | Immunotherapy for prostate cancer | Phase 1/2a studies permitted by FDA |
| Bria-MEL+ | Personalized whole cell melanoma immunotherapy vaccine candidate | Advancing toward clinical development |
| Line | FY ended Jul 31, 2026 | FY ended Jul 31, 2025 |
|---|---|---|
| Research and development | $29.2 million | $21.3 million |
| Net income (loss) | -$34.9 million | -$26.3 million |
| Cash from operations | -$28.7 million | -$28.2 million |
| Cash and equivalents | $9.9 million | $10.5 million |
| Short-term investments | $10.7 million | $7.4 million |
BriaCell Therapeutics Corp trades under the ticker BCT on TSX.
BriaCell Therapeutics Corp is listed on TSX. Our directory also records these other listings: GETTEX:8BT; NASDAQ:BCTX; NEO:BCT.
The SEC Central Index Key (CIK) for BriaCell Therapeutics Corp is 1610820. Its filings are on SEC EDGAR.
8,699,787 shares as of 2026-06-09, per the cover page of its 10-Q filed 2026-06-09.
Our directory records BriaCell Therapeutics Corp under Canada.
Our directory classifies BriaCell Therapeutics Corp as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for BriaCell Therapeutics Corp is CA1079303071.
aibio.space lists BriaCell Therapeutics Corp among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as A1.
BriaCell Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies to treat cancer. Its lead candidate, Bria-IMT, is being advanced in combination with the immune checkpoint inhibitor Retifanlimab in a pivotal Phase 3 study in metastatic breast cancer, and it is under Fast Track Designation from the U.S. Food and Drug Administration.
Bria-IMT: Targeted immunotherapy combined with Retifanlimab for metastatic breast cancer Stage: Pivotal Phase 3 study.
Bria-OTS: Personalized off-the-shelf immunotherapy for metastatic breast cancer Stage: Phase 1/2.
BriaCell Therapeutics Corp reported a net loss of $34.9 million for the fiscal year ended Jul 31, 2026, and used $28.7 million of cash in operations, per its annual report to the SEC.
$29.2 million in the fiscal year ended Jul 31, 2026, per its annual report.
$20.5 million in cash and short-term investments at Jul 31, 2026, per its 10-K.
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B4. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 7.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form S-1. Source
Reported a financing. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio